A noninvasive functional lesion of the hypothalamo-pituitary axis for the study of growth hormone-releasing factor.
Rats were passively immunized with an antiserum against somatostatin and a monoclonal antibody against rat hypothalamic growth hormone-releasing factor (rGRF-mAb) which does not recognize the biologically active 1-40 amino acid fragment of hpGRF-44 (hpGRF-40). Using this paradigm we have observed that the pituitary possesses a resilient capacity to release growth hormone (GH) following repeated injections of hpGRF-40 and that this response follows a dose-dependent relationship.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D013007:Growth Hormone-Releasing Hormone / Q000494:pharmacology / Q000502:physiology*; D007030:Hypothalamo-Hypophyseal System / Q000502:physiology*; D008297:Male; D010446:Peptide Fragments / Q000494:pharmacology; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D013004:Somatostatin / Q000276:immunology
D000911:Antibodies, Monoclonal; D010446:Peptide Fragments; C036893:somatotropin releasing factor 40; D013004:Somatostatin; D013007:Growth Hormone-Releasing Hormone